Literature DB >> 16525649

Effects of PPAR and RXR ligands in semaphorin 6B gene expression of human MCF-7 breast cancer cells.

Hossam Murad1, Philippe Collet, Cecile Huin-Schohn, Nehmann Al-Makdissy, Geraldine Kerjan, Alain Chedotal, Mireille Donner, Marie Dominique Devignes, Philippe Becuwe, Herve Schohn, Lionel Domenjoud, Michel Dauça.   

Abstract

This study tests the hypothesis that the activators of peroxisome proliferator-activated receptors (PPARs) and 9-cis-retinoic acid receptor (RXR) regulate human semaphorin 6B (Sema6B) gene expression. The human MCF-7 breast adenocarcinoma cell line was chosen because it expresses Sema6B at a high level. The Sema6B mRNA level was analyzed by RT-PCR and the semaphorin 6B protein content was determined using a polyclonal antibody that we have produced and characterized. Treatments with fenofibrate (a PPARalpha activator) and troglitazone (a PPARgamma ligand) strongly decreased the Sema6B mRNA. The drop in Sema6B mRNA level and in protein content was more important when the treatment combined the action of fenofibrate or troglitazone and 9-cis-retinoic acid. On the other hand, no significant change was observed in the Sema6B mRNA and protein levels when the cells were exposed to the combined action of GW610742 (a PPARbeta activator) and 9-cis-retinoic acid. These data suggest that PPARalpha/RXR and PPARgamma/RXR heterodimers are involved in the regulation of Sema6B gene expression and open new perspectives concerning the participation of these nuclear receptors in cell recognition and migration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16525649

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

Review 1.  Transmembrane semaphorins: Multimodal signaling cues in development and cancer.

Authors:  Sreeharsha Gurrapu; Luca Tamagnone
Journal:  Cell Adh Migr       Date:  2016-06-13       Impact factor: 3.405

2.  Fenofibrate potentiates chemosensitivity to human breast cancer cells by modulating apoptosis via AKT/NF-κB pathway.

Authors:  Jianguo Sun; Zhibao Zheng; Qi Chen; Yin Pan; Mingming Quan; Yuechu Dai
Journal:  Onco Targets Ther       Date:  2019-01-23       Impact factor: 4.147

3.  Association of a Novel Prognosis Model with Tumor Mutation Burden and Tumor-Infiltrating Immune Cells in Thyroid Carcinoma.

Authors:  Siqin Zhang; Shaoyong Chen; Yuchen Wang; Yuxiang Zhan; Jiarui Li; Xiaolin Nong; Biyun Gao
Journal:  Front Genet       Date:  2021-12-17       Impact factor: 4.599

4.  SEMA6B Overexpression Predicts Poor Prognosis and Correlates With the Tumor Immunosuppressive Microenvironment in Colorectal Cancer.

Authors:  Tiegang Li; Zheng Yan; Weiqi Wang; Rixin Zhang; Wenqiang Gan; Silin Lv; Zifan Zeng; Yufang Hou; Min Yang
Journal:  Front Mol Biosci       Date:  2021-12-06

5.  Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway.

Authors:  Ting Li; Qunling Zhang; Jian Zhang; Gong Yang; Zhimin Shao; Jianmin Luo; Minhao Fan; Chen Ni; Zhenhua Wu; Xichun Hu
Journal:  BMC Cancer       Date:  2014-02-16       Impact factor: 4.430

Review 6.  Anticancer Properties of Fenofibrate: A Repurposing Use.

Authors:  Xin Lian; Gang Wang; Honglan Zhou; Zongyu Zheng; Yaowen Fu; Lu Cai
Journal:  J Cancer       Date:  2018-04-06       Impact factor: 4.207

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.